Authors
Alessia Di Pauli, Rosa Vona, Alice Di Netta, Camilla Cittadini, Marika Berardini, Stefania Meschini, Maria Condello
Published in
Molecular biology reports. Volume 53. Issue 1. Jul 10, 2026. Epub Jul 10, 2026.
Abstract
Melanoma is one of the most aggressive forms of cancer in human due to its ability to invade tissues and metastasize. The aim of this work is to examine the effect of our patented compound Prunus spinosa Trigno + Nutraceutical Activator Complex (PsT + NAC®) on primary (WM115), metastatic (WM266-4), and malignant (A375) human melanoma cell lines.
The data show that PsT + NAC® induced a dose- and time-dependent reduction in cell viability in all melanoma cell lines, particularly in the metastatic WM266-4. Persistent morphological changes indicative of cell death were observed, which remained irreversible even after the cells recovered from treatment. The treatment with PsT + NAC® altered cell migration and motility by remodeling of actin cytoskeleton. Cell cycle analysis revealed a G2/M phase arrest in the primary WM115 cells, and a G1 phase arrest-at lower concentrations-in the metastatic WM266-4 cells, and in the malignant A375 cells. As the treatment concentration increased, all melanoma cell lines showed an increase in the sub-G1 population, associated with apoptosis. Western blotting analysis revealed that lower concentrations of PsT + NAC® induced a protective autophagic response, while higher concentrations triggered caspase-dependent apoptosis.
These results demonstrate the efficacy of PsT + NAC® in inhibiting the growth of BRAF-mutant melanoma cells.
PMID:
42429842
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0